Species differences in the disposition and metabolism of nalidixic acid

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 222-230

  Nomeir, Amin A ^a,c   Markham, Peter ^a   Burka, L T ^b   Griffin, Robert J ^b   Ghanayem, Burhan I ^b  

^a Arthur D Little Inc   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALIDIXIC ACID;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CLITORIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CARCINOGENICITY; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; GENITAL TRACT CANCER; LIVER; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREPUTIAL GLAND; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; MALE; MICE; NALIDIXIC ACID; ORGAN SPECIFICITY; RATS; RATS, INBRED F344; SPECIES SPECIFICITY;

EID: 0030425690     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. CRUMPLIN, G. C.: The involvement of DNA topoisomerases in DNA repair and mutagenesis. Carcinogenesis 2: 157-160, 1981.
2. CUISINAUD, G., FERRY, N., SECCIA, M., BERNARD, N. AND SASSARD, J.: Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phaae high-performance liquid chromatography. J. Chromatogr. 181: 399-406, 1980.
3. GIBBON, N. O., BENSTEAD, J. G. AND MISRA, G. C.: A comparative study of the levels of nalidixic acid in plasma and urine and its antibacterial activity in urinary infections of paraplegics. Postgrad. Med. J. 41: 501-508, 1965.
4. GLECKMAN, R., ALVAREZ, S., JOUBERT, D. W. AND MATTHEWS, S. J.: Drug therapy reviews: Nalidixic acid. Am. J. Hosp. Pharm. 36: 1071-1076, 1979.
5. HARRISON, L. H. AND COX, C. E.: Bacteriologic and pharmacodynamic aspects of nalidixic acid. J. Urol. 104: 908-913, 1970.
6. HARVEY, F. AND EDELSON, J.: Species differences in the hepatic microsomal oxidation of nalidixic acid. Arch. Int. Pharmacodyn. Ther. 229: 192-198, 1977.
7. HOEPRICH, P. D.: New antimicrobics for the treatment of infections caused by gram-negative bacilli. Med. Clin. North Am. 51: 1127-1152, 1967.
8. IMS AMERICA LTD.: Hazardous substances databank. Bethesda, MD, 1988.
9. KANISAWA, M., KATO, H. AND AISO, K.: Carcinogenicity of potassium 1-methyl-7-[2-(5-nitro-2-furyl)-vinyl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3- carboxylate in ICR mice. Gann 65: 1-11, 1974.
10. 1 mice. Food Chem. Toxicol. 24: 319-323, 1986.
11. MÄNNISTÖ, P. T.: Pharmacokinetics of nalidixic acid and oxolinic acid in healthy women. Clin. Pharmacol. Ther. 19: 37-46, 1976.
12. MCCHESNEY, E. W., FROELICH, E. J., LESHER, G. Y., CRAIN, A. V. R. AND ROSI, D.: Absorption, excretion, and metabolism of a new antibacterial agent, nalidixic acid. Toxicol. Appl. Pharmacol. 6: 292-309, 1964.
13. MCCHESNEY, E. W., PORTMANN, G. A. AND KOSS, R. F.: Pharmacokinetic model for nalidixic acid in man. 3. Effect of repeated oral dosage. J. Pharm. Sci. 56: 594-599, 1967.
14. MOORE, W. E., PORTMANN, G. A., STANDER, H. AND MCCHESNEY, E. W.: Biopharmaceutical investigation of nalidixic acid in man. J. Pharm. Sci. 54: 36-41, 1965.
15. MORRISSEY, R. E., EUSTIS, S., HASEMAN, J. K., HUFF, J. AND BUCHER, J. R.: Toxicity and carcinogenicity studies of nalidixic acid in rodents. Drug Chem. Toxicol. 14: 45-66, 1991.
16. NTP TECHNICAL REPORT # 368: Toxicology and Carcinogenicity Studies of Nalidixix Acid (CAS no. 38908-02) in F344/N Rats and B6C3F1 Mice (Feed Studies). U. S. Department of Health and Human Services, NIH Publication no. 90-2823, Bethesda, MD, 1989.
17. PORTMANN, G. A., MCCHESNEY, E. W., STANDER, H. AND MOORE, W. E.: Pharmacokinetic model for nalidixic acid in man. I. Kinetic pathways for hydroxynalidixic acid. J. Pharm. Sci. 55: 59-62, 1966a.
18. PORTMANN, G. A., MCCHESNEY, E. W., STANDER, H. AND MOORE, W. E.: Pharmacokinetic model for nalidixic acid in man. II. Parameters for absorption, metabolism, and elimination. J. Pharm. Sci. 55: 72-78, 1966b.
19. ROSSOFF, I. S.: Handbook of Veterinary Drugs. Springer, New York, 1974.
20. STAMEY, T. A., NEMOY, N. J. AND HIGGENS, M.: The clinical use of naliduxic acid: A review and some observations. Invest. Urol. 6: 582-591, 1969.
21. STAMEY, T. A., MEARS, E. M. AND WINNINGHAM, D. G.: Chronic bacterial prostatitis and diffusion of drugs in prostatic fluid. J. Urol. 103: 187-194, 1970.